Several preclinical and clinical trials of potential immunomodulatory drugs have been investigated in HD, such as minocycline and cannabinoids, laquinimod, TNF-α inhibitors, anti-SEMA4D monoclonal antibody, gangliosides and so on. Here, TNF is linked to Huntington disease.